Abstract
Abstract Background: Mortality is a critical variable in healthcare research, but inconsistencies in the availability of death date and cause of death (CoD) information limit the ability to monitor medical product safety and effectiveness. Objective: To develop scalable approaches using natural language processing (NLP) and large language models (LLM) for the extraction of mortality information from publicly available online data sources, including social media platforms, crowdfunding websites, and online obituaries. Methods. Data were collected from public posts on X (formerly Twitter), GoFundMe campaigns, memorial websites (EverLoved.com and TributeArchive.com), and online obituaries from 2015 to 2022. We developed a natural language processing (NLP) pipeline using transformer-based models to extract key mortality information such as decedent names, dates of birth, and dates of death. We then employed a few-shot learning (FSL) approach with large language models (LLMs) to identify primary and secondary causes of death. Model performance was assessed using precision, recall, F1-score, and accuracy metrics, with human-annotated labels serving as the reference standard for the transformer-based model, and a human adjudicator blinded to labeling source for the FSL model reference standard. Results: The best-performing model obtained a micro-averaged F1-score of 0.88 in extracting mortality information. The FSL-LLM approach demonstrated high accuracy in identifying primary causes of death across various online sources. For GoFundMe, the FSL-LLM achieved 95.9% accuracy for primary cause identification, compared to 97.9% for human annotators. In obituaries, FSL-LLM accuracy was 96.5% for primary causes, while human accuracy was 98.9%. For memorial websites, FSL-LLM achieved 97.9% accuracy for primary causes, with human accuracy at 98.9%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding statement: This project was supported by Task Order 75F40123F19010 under Master Agreement 75F40119D10037 from the US Food and Drug Administration (FDA). FDA coauthors reviewed the study protocol, statistical analysis plan, and the manuscript for scientific accuracy and clarity of presentation. Representatives of the FDA reviewed a draft of the manuscript for presence of confidential information and accuracy regarding statement of any FDA policy. The views expressed are those of the authors and not necessarily those of the US FDA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
